Prelude Therapeutics partners with Eli Lilly to supply drugs for Phase 1 breast cancer trial
Prelude Therapeutics announced a clinical‑trial and supply agreement with Eli Lilly to evaluate its candidate PRT13722 together with Lilly’s abemaciclib and imlunestrant in a Phase 1 study for HR+/HER2‑ breast cancer. The U.S. FDA cleared the IND for PRT13722, and enrollment is slated to begin in the fourth quarter of 2026. Prelude will retain full global development and commercial rights to PRT13722.
Why it matters
The collaboration gives Prelude access to Lilly’s established breast‑cancer agents, potentially accelerating data generation for PRT13722 and enhancing its commercial prospects if the trial shows positive results. The company’s forward‑looking statements indicate the deal is expected to support its pipeline and cash‑flow outlook.
Key facts
- 1The agreement supplies Lilly’s abemaciclib and imlunestrant for combination testing with Prelude’s PRT13722. stocktitan.net
- 2The FDA cleared the IND for PRT13722, allowing the Phase 1 study to proceed. stocktitan.net
- 3Patient enrollment is expected to start in the fourth quarter of 2026. stocktitan.net
- 4Prelude retains full global development and commercial rights to PRT13722. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.